Interventional Cardiology, Radiology and Neuroradiology, Cardiac Rhythm Management and Electrophysiology (CRM and EP)

Cardiac Rhythm Management devices perform many functions, including bradycardia pacing, monitoring for arrhythmias, cardiac resynchronisation for heart failure, defibrillation and anti-tachycardia pacing for tachyarrhythmias. Products include but not are limited to: — pacemakers, — implantable cardiac defibrillators (ICD), — cardiac re-synchronisation therapy (CRT), — loop recorders, — lead extension, — lead extraction, — temp pacing machines, — pacing system analysers, — home monitoring, — accessories. Electrophysiology products are critical to performing ablation of the heart to avoid irregular electrodes and irregular movement of the heart. Products include but not are limited to: — catheters, — electrophysiology equipment e.g. generators, — patches, — introducer sheaths, — accessories. Additional information: Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of 170 000 000 GBP to 250 000 000 GBP in the first year of this framework agreement, however this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.

Medical consumable devices to be used to support cardiac related procedures set in a catheter laboratory environment. Products include but not limited to: — guide catheters, — sheaths-introducer and delivery, — percutaneous coronary intervention (PCI) guidewires, — drug eluting balloons, — speciality cutting balloons, — vascular closure devices, — coronary diagnostics pressure wire, — coronary diagnostics intravascular ultrasound imaging and occular coherence, — tomography imaging consumables, — aspiration catheters, — micro catheters, — rotablator burrs and wires, — specialist kit, — aneurysm coils and flow diverters for intracranial aneurysms, — endovascular stent grafts, — cartoid lliac and renal stents, — intracranial stents, — occluder vasculer appendage and septal devices, — peripheral vascular stents, — Diagnostic and interventional. Additional information: Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of 250 000 000 GBP to 290 000 000 GBP in the first year of this framework agreement, however this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.